The world of medicine is undergoing a paradigm shift, challenging long-held beliefs about the nature of diseases. A groundbreaking study from the University of California, Los Angeles (UCLA), published in 2025, has revealed a startling connection between viral infections and chronic illnesses, particularly cardiovascular disease (CVD). This revelation is a game-changer, offering a new perspective on how we approach and understand disease prevention and management.
The Hidden Link: Viruses and Chronic Diseases
The UCLA study, led by Dr. Kosuke Kawai, analyzed an extensive body of research, reviewing 155 studies, and found a significant association between viral infections and an increased risk of cardiovascular events. Acute infections, such as influenza and SARS-CoV-2, were linked to a four-fold increase in heart attacks and a five-fold rise in stroke risk within the first month after infection. Even long-term infections like HIV, hepatitis C, and herpes zoster were not exempt, showing higher risks for coronary heart disease (CHD) and stroke.
This study's findings challenge the traditional division between infectious and non-communicable diseases. It suggests that many chronic conditions, often considered separate entities, are, in fact, the delayed consequences of infections. The authors emphasize that viral infections are "underrecognized and potentially preventable contributors" to the global CVD burden.
A Controversial Policy Paradox
However, this new understanding stands in stark contrast to the federal public health policy announced by Robert F. Kennedy Jr., an anti-science figure placed in charge of the Department of Health and Human Services. Kennedy's approach, which includes anti-vaccine positions and a reduction in investment in immunization, contradicts the emerging scientific consensus. By separating vaccination and infection surveillance from chronic-disease prevention, Kennedy's policy ignores the very link between infection and non-communicable illnesses, with significant implications for public health.
Viral Infections: Acute and Chronic Risks
The UCLA team's meta-analysis highlights two critical aspects of viral impact on cardiovascular health: the acute, short-term risk following infection and the chronic, long-term burden from persistent viral diseases. For acute infections, the evidence is compelling. Laboratory-confirmed influenza infection, for instance, was linked to a four-fold increase in heart attacks and a five-fold increase in strokes within the first month. COVID-19 also showed consistent cardiovascular effects, with a three-fold higher risk of myocardial infarction or stroke during the first year post-infection. Long-term follow-up indicated a 74% higher risk of CHD and a 69% higher risk of stroke among those previously infected.
The study also revealed that viral infections can cause lasting cardiovascular damage. HIV infection was associated with a 60% long-term increase in CHD risk, a 45% higher stroke risk, and nearly double the risk of heart failure. Hepatitis C virus (HCV) and varicella-zoster virus (herpes zoster) infections were also linked to increased CHD and stroke risks, lasting up to a decade after infection.
Infections: The Upstream Drivers
Beyond cardiovascular issues, a wide range of cancers, autoimmune conditions, and neurological disorders are now understood to be initiated or exacerbated by infectious agents. A 2020 study estimated that 130 million disability-adjusted life years (DALYs) from non-communicable diseases are attributable to infection, a conservative estimate.
This reconceptualization has profound policy implications. Recognizing that chronic diseases often have infectious origins opens up opportunities to prevent irreversible outcomes by tackling infections early. This paradigm shift demands a transformation in how we approach disease prevention, integrating vaccination, surveillance, and pathogen elimination into chronic-disease prevention frameworks.
The COVID-19 Pandemic: A Case Study
The COVID-19 pandemic serves as a large-scale example of how a single infectious agent can lead to a massive non-communicable disease burden. By October 2024, confirmed COVID-19 deaths in the US exceeded 1.2 million. However, the true toll is measured through excess mortality, which includes deaths from all causes above pre-pandemic trends. Between 2020 and 2023, the US experienced approximately 3.63 million excess deaths. A significant portion of these deaths is attributed to infection-related cardiovascular and metabolic complications.
The so-called "let-it-rip" policy, characterized by premature reopenings and minimal infection control, has allowed uncontrolled viral spread. This strategy, based on the false premise of population immunity through mass infection, has resulted in preventable deaths, disabilities, and chronic illnesses. The COVID-19 case study underscores the interconnectedness of infectious-disease policy and chronic-disease prevention.
Cardiovascular Mortality and Long COVID
The pandemic has also reversed decades of progress in US heart-disease prevention, with an estimated 228,524 excess cardiovascular deaths between 2020 and 2022. Younger adults experienced the sharpest relative rise in heart-attack mortality rates. This surge in cardiovascular deaths points to a hidden epidemic of Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC). Long COVID is associated with increased risks of cardiovascular disease, stroke, diabetes, kidney impairment, and autoimmune disorders.
The true annual toll of COVID-19 deaths in the US is estimated to be about 36% higher than reported figures, with analysts estimating between 78,000 and 94,000 deaths annually. This ongoing mortality, alongside the rise in cardiovascular deaths, highlights the long-term, infection-mediated burden left by the pandemic.
Debunking the Anti-Vaccine Myth
The surge in cardiovascular mortality during the pandemic has been exploited by anti-vaccine movements as evidence that COVID-19 vaccines cause excess heart attacks and strokes. However, epidemiological data shows that this upswing began in early 2020, well before any COVID-19 vaccine was authorized. Excess cardiovascular mortality closely tracked infection waves, not vaccination campaigns. Large systematic reviews of vaccination and cardiovascular outcomes further refute the anti-vax narrative, showing no consistent increase in heart attack, stroke, or arrhythmia following COVID-19 vaccination.
The Socioeconomic Impact
The intersection of chronic disease, infectious triggers, and patient outcomes is deeply influenced by socioeconomic factors, leading to significant inequities in morbidity and mortality. Individuals in low-income communities face higher cardiovascular hospitalization rates and greater burdens of diabetes, hypertension, and chronic respiratory disease. When COVID-19 struck, these preexisting inequities resulted in a disproportionate toll on lower-income and minority populations.
Studies have shown that an 18% vaccination gap between major demographic groups contributes significantly to disparities in CVD mortality. On a global scale, the burden of infection-related NCDs falls most heavily on the Global South, particularly sub-Saharan Africa, where inadequate infrastructure and reduced vaccination coverage perpetuate high rates of infection-driven chronic illness.
Vaccination: A Protective Measure
Vaccines offer demonstrable protection against cardiovascular disease triggered by infection. The major UCLA meta-analysis confirmed that viral infections like SARS-CoV-2, influenza, and herpes zoster substantially elevate cardiovascular risk, highlighting the preventive role of vaccination. A 2025 study found that pre-infection COVID-19 vaccination reduced the risk of major acute cardiovascular events (MACE) by 30% and all-cause mortality by 70% in the year following infection.
Further studies have quantified this protective effect across multiple pathogens and vaccine types. The landmark Influenza Vaccination After Myocardial Infarction (IAMI) trial demonstrated that administering an influenza vaccine during hospitalization for an acute myocardial infarction reduced cardiovascular death and major adverse events by 41% over one year. Comparable findings extend to COVID-19 vaccination, with a 2024 meta-analysis reporting no overall increase in risk of heart attack, arrhythmia, or stroke following vaccination, and a clear protective trend after booster doses.
Vaccination as a Cornerstone of Cardiovascular Prevention
The European Society of Cardiology's 2025 Clinical Consensus Statement, "Vaccination as a New Form of Cardiovascular Prevention," represents a historic shift in cardiovascular medicine. For the first time, the ESC formally recognized infectious-disease prevention, particularly through vaccination, as a foundational pillar of cardiovascular prevention. The statement codifies the multi-phase mechanisms by which infectious agents damage the heart and the cardiovascular system, affirming that vaccination is a core intervention in chronic-disease prevention.
The ESC panel's synthesis of evidence establishes that immunization is a cardiovascular intervention, conferring quantifiable reductions in heart-attack, stroke, and mortality risk, comparable to medication-based therapies. The ESC declares that vaccination rates should now be treated as population-level indicators of cardiovascular health, equal in importance to hypertension or cholesterol control. This re-orientation mandates a global policy shift, integrating immunization into standard cardiovascular-prevention guidelines and funding vaccine access as part of chronic-disease programs.
Conclusion: The Life Expectancy Crisis and the Need for Transformation
The new understanding of non-communicable diseases as downstream consequences of infection marks a turning point in medical science, comparable to the germ theory revolution. This breakthrough reveals that many chronic diseases once attributed to "lifestyle" or heredity are, in fact, the biological aftermath of previous infections. However, this consensus is now facing a historic life-expectancy crisis. In the US, life expectancy fell from 78.8 years in 2019 to 76.4 years in 2021, the largest two-year decline since World War II. This reversal erased two decades of progress, with national longevity returning to its 2001 level.
The contraction of US lifespan, despite enormous growth in scientific and medical capacity, reveals a structural failure: the subordination of public health to private profit. The catastrophic decline in life expectancy cannot be understood apart from the social system that produced it. The same political forces that weaponize anti-vaccine narratives are responsible for this decline. The defense of life expectancy and the restoration of public health require a revolutionary transformation, aligning the means of production and life with human need rather than private gain. The struggle for public health is, therefore, inseparable from the struggle for socialism, a revolutionary fight for life, longevity, and the future of humanity.
